Satiogen Pharmaceuticals Inc

Satiogen Pharmaceuticals has discovered a metabolic mechanism of action – termed “the bile acid brake” – that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed drugs or invasive surgical methods.  Preclinical experiments testing several druggable concepts have demonstrated metabolic effects comparable to marketed drugs, and clinical studies have extended these findings to humans. Since starting in 2007 Satiogen has operated as a virtual company focused on demonstrating proof-of-concept and crafting a patent estate.  In 2010 Satiogen out-licensed its lead pharmaceutical technology to Lumena Pharmaceuticals, which was purchased by Shire PLC in 2014; because Shire is focused on the orphan drug indications being developed by Lumena, in late 2016 Shire returned to Satiogen patent claims directed to diabetes and obesity.

The bile acid brake is a metabolic regulatory mechanism which potently suppresses food intake and plasma glucose when excessive amounts of bile acids arrive in the colon and rectum.  These bile acids are ligands for intraluminal G-protein coupled bile acid receptors on colorectal L-cells which secrete multiple metabolic hormones that regulate satiety and glucose homeostasis via mechanisms predicted to be cardioprotective.  This intraluminal, nonsystemic mechanism of action offers an important safety advantage for therapeutic products:  non-absorbed drugs are intrinsically safer than drugs which must be systemically bioavailable.

Satiogen has focused its efforts on two activities: preclinical and clinical research on alternative product concepts for triggering the bile acid brake, including three druggable ideas and a medical device: and crafting a patent portfolio that will control freedom to operate in these product areas.  Several of Satiogen’s patent applications have been approved by the USPTO and various foreign patent authorities, and the company is seeking licensees and collaborators to pursue development of these drug concepts.